Ionis Prescription drugs, Inc. (NASDAQ:IONS) is among the
8 Most Promising Biotech Stocks to Buy Now.
On April 30, Oppenheimer raised its value goal on Ionis Prescription drugs, Inc. (NASDAQ:IONS) from $104 to $111. It maintained an “Outperform” ranking on the inventory whereas noting shares rose after first-quarter outcomes and up to date steering.
On April 29, Ionis Prescription drugs, Inc. (NASDAQ:IONS) reported first-quarter 2026 outcomes. Rising demand for TRYNGOLZA is pushed by launch execution whereas elevating full-year income steering.
The corporate stated the FDA accepted the olezarsen sNDA for precedence evaluation, with launch preparations for extreme hypertriglyceridemia progressing, whereas rising peak internet gross sales steering for TRYNGOLZA to over $3 billion.
The pipeline superior. The agency stated the FDA accepted the “zilganersen NDA” for precedence evaluation, positioning its first unbiased neurology launch.
CEO Brett Monia summed it up just by stating that the enterprise is performing nicely on each the industrial and R&D fronts. He famous future Section 3 readouts and launches for olezarsen and zilganersen this 12 months.
Ionis Prescription drugs, Inc. (NASDAQ:IONS) is a agency that develops and markets human therapeutic medicine utilizing antisense know-how. It’s primarily based in Carlsbad, California.
Whereas we acknowledge the potential of IONS as an funding, we consider sure AI shares provide better upside potential and carry much less draw back danger. When you’re in search of a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
